Supplementum 281: Abstracts of the Annual meeting of the Swiss Society of Gastroenterology, the Swiss Society of Visceral Surgery, the Swiss Association for the Study of the Liver and the Swiss Society of Endoscopy Nurses and Associates (Interlaken,

Background: While the efficacy of the oral, reversible and selective Janus kinase inhibitor Upadacitinib (UPA) in UC was established in clinical studies, real-world data remains scarce.Methods: EUROPE is a prospective, non-interventional, multicountry study in patients with active UC who initiate therapy with UPA.Here, we report first results of 124 patients at baseline (BL), week 2 (2W) and week 8 (8W).For 75 patients, sonographic BL data was available.Results: 85.5% of patients were bio-experienced (n = 106; n = 35 had 3 biologicals).Disease activity per paMayo score was 3.0 (2.0-5.0)points.After UPA induction, symptomatic remission rate (normal stool frequency and no rectal bleeding) improved from 16.9% (n = 21) at BL to 43.5% (n = 54) at 2W and to 64.5% (n = 80) at W8 (both p<0.001 vs. BL).Bowel wall thickness was reduced from a median of 5.0 mm (3.8-7.0) at BL to 3mm in more than half of all patients as early as 2W (n = 48; p <0.001).Of 156 patients included in the safety analysis, 23.7% (n = 37) experienced an adverse event which was mostly nonserious. Conclusion:UPA treatment in UC was associated with early clinical and sonographic improvement, with most patients achieving symptomatic remission and/or normalization of BWT by week 8 of treatment.